Morgan, Leslie E.
Jaramillo, Ana M.
Shenoy, Siddharth K. http://orcid.org/0000-0001-7937-8978
Raclawska, Dorota
Emezienna, Nkechinyere A.
Richardson, Vanessa L.
Hara, Naoko
Harder, Anna Q.
NeeDell, James C.
Hennessy, Corinne E.
El-Batal, Hassan M.
Magin, Chelsea M.
Grove Villalon, Diane E.
Duncan, Gregg http://orcid.org/0000-0002-6811-1327
Hanes, Justin S.
Suk, Jung Soo http://orcid.org/0000-0002-2437-0001
Thornton, David J. http://orcid.org/0000-0001-7148-1970
Holguin, Fernando
Janssen, William J.
Thelin, William R.
Evans, Christopher M. http://orcid.org/0000-0001-5600-7314
Funding for this research was provided by:
NSF | Directorate for Mathematical & Physical Sciences | Division of Materials Research (1941401)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL080396, HL080396, HL080396, HL130938)
RCUK | Medical Research Council (MR/R002800/1)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (ES023384)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Cystic Fibrosis Foundation (EVANS18IO)
Article History
Received: 6 September 2019
Accepted: 20 November 2020
First Online: 11 January 2021
Competing interests
: The muco-inert particle technology described in this article is being developed by Kala Pharmaceuticals. J.H. declares a financial, a management/advisor, and a paid consulting relationship with Kala Pharmaceuticals. J.H. is a cofounder of Kala Pharmaceuticals and owns company stock, which is subject to certain restrictions under Johns Hopkins University policy. C.E. is a paid consultant with Eleven P15, a company focused on early detection and treatment of pulmonary fibrosis. C.M. is a paid consultant with Sharklet Technologies, a company that uses surface texture to reduce biological adhesion to medical devices. The terms of these arrangements are being managed by Johns Hopkins University and the University of Colorado in accordance with respective institutional conflict-of-interest policies. W.T. and D.V. are employees of Parion Sciences, Inc., a company that designs and tests novel mucolytic agents. No proprietary mucolytic agents were used in this study. All other authors declare no conflicts of interest.